Rare-disease PRV vouchers sell for $155M — here's an AI-native business model to farm them
NikoMcCarty · x · 2026-09-26
A concrete business idea around FDA priority review vouchers (PRVs) for rare pediatric diseases:
- Mechanism: approval of a qualifying rare pediatric drug earns a PRV that can be sold — often well over $100M; Abeona sold one for $155M (tracked on PRV Watch).
- Play: pick ultra-rare diseases where trials of 5-10 patients suffice, use computational tools to raise success odds, and drive cost to $5-10M per drug.
- Math: run ten shots at once; one PRV sale covers the whole tranche, then reinvest into more cures.
- Deadline: the program is authorized only through September 30, 2029, so speed and lobbying for extensions matter.
Traditional pharma skips these diseases for R&D-recovery reasons; AI plus a small team could profit while filling unmet needs.
More from Venture
- Polymarket: Grok Drives 59.5% of AI-Agent Trading Volume on Coinbase vs Claude's 13.4% — Polymarket · 2026-09-26
- AI consultant's postmortem: website design and podcast production sell best — StewartalsopIII · 2026-09-26
- Your AI business case is probably resting on the wrong assumption — zeuslac · 2026-09-26
- ChatGPT Drives ~75% of AI Referral Traffic, but Converts Under 2% — nikvassev · 2026-09-26
- Polymarket prices AI bubble burst at just 10% as traders bet on the boom holding — Polymarket · 2026-09-26
- When an AI engine names your brand, buyers decide in-answer and show up as direct — nikvassev · 2026-09-26